-

$undefined

N/A

(N/A)

Gossamer Bio NASDAQ:GOSS Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

Location: 3013 Science Park Rd, California, 92121-1101, US | Website: www.gossamerbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

90.14M

Cash

294.5M

Avg Qtr Burn

-867K

Short % of Float

3.13%

Insider Ownership

3.28%

Institutional Own.

76.51%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details Rare diseases, Pulmonary arterial hypertension, Lung disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Seralutinib (GB002) Details Lung disease, Pulmonary hypertension associated with interstitial lung disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB001 (Oral DP2 Antagonist) Details Asthma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB004 (Oral HIF-1α stabilizer) Details Ulcerative colitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB1275 (Oral CD11b modulator) Details Solid tumor/s, Esophageal cancer, Cancer, Gastric cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.